Kwame Addo
Psychiatric/Mental Health · Killeen, TXNPI 1598395063
Payments from drug & device makers
Across 15 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$152
- Takeda Pharmaceuticals U.S.A., Inc.$45
- Lundbeck LLC$45
- Indivior Inc.$29
- E.r. Squibb & Sons, L.L.C.$24
- Corium, LLC$23
- plus $52 from 3 others
What the payments were for
- Food & beverage$36499%
- Education$51%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $152 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Lundbeck LLC | 2 | $45 |
| Indivior Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Corium, LLC | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$127
How this compares
$370 in reported general payments places this provider in the 40th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 25 | $211,627 |
| Invega SustennaPaliperidone Palmitate | 25 | $48,139 |
| RexultiBrexpiprazole | 12 | $20,485 |
| Paliperidone ErPaliperidone | 38 | $6,252 |
| Bupropion XlBupropion Hcl | 76 | $2,552 |
| Buspirone Hcl | 173 | $1,970 |
| Lurasidone Hcl | 43 | $1,668 |
| Aripiprazole | 37 | $1,573 |
| Ziprasidone Hcl | 18 | $1,547 |
| Quetiapine Fumarate | 139 | $1,479 |
| Duloxetine Hcl | 43 | $1,170 |
| Hydroxyzine Pamoate | 95 | $838 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 56 | $670 |
| Mirtazapine | 45 | $655 |
| Trazodone Hcl | 90 | $651 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Killeen
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
- Jaime Nelson DensonAustin$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.